Detalhe da pesquisa
1.
Germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across solid tumor types.
Immunity
; 55(1): 56-64.e4, 2022 01 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34986342
2.
Concordance between an FDA-approved companion diagnostic and an alternative assay kit for assessing homologous recombination deficiency in ovarian cancer.
Gynecol Oncol
; 184: 67-73, 2024 Jan 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38290412
3.
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100.
Gynecol Oncol
; 178: 119-129, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37862791
4.
Concordance between single-nucleotide polymorphism-based genomic instability assays and a next-generation sequencing-based homologous recombination deficiency test.
BMC Cancer
; 22(1): 1310, 2022 Dec 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36517748
5.
Identification of predictive genetic signatures of Cytarabine responsiveness using a 3D acute myeloid leukaemia model.
J Cell Mol Med
; 23(10): 7063-7077, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31449347
6.
Integrative analysis of diffusion-weighted MRI and genomic data to inform treatment of glioblastoma.
J Neurooncol
; 129(2): 289-300, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27393347
7.
[Malyugin ring--an alternative in the treatment of a miotic pupil]. / Inelul malyugin--alternativa în tratamentul pupilei "refractare".
Oftalmologia
; 58(2): 40-2, 2014.
Artigo
em Ro
| MEDLINE | ID: mdl-25300128
8.
Biomarker Testing Journey Among Patients with Advanced Solid Tumors and Treatment Patterns by Homologous Recombination Repair Status: A Clinico-Genomic Database Study.
Adv Ther
; 41(2): 759-776, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38169059
9.
Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146.
J Immunother Cancer
; 12(1)2024 01 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38242717
10.
Real-world prevalence of homologous recombination repair mutations in advanced prostate cancer: an analysis of two clinico-genomic databases.
Prostate Cancer Prostatic Dis
; 2023 Dec 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38057611
11.
Association Between Homologous Recombination Repair Biomarkers and Survival in Patients With Solid Tumors.
JCO Precis Oncol
; 7: e2300195, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37972338
12.
Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC.
JTO Clin Res Rep
; 4(1): 100431, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36793385
13.
Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial.
J Immunother Cancer
; 11(6)2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37399357
14.
Biomarkers predictive of response to pembrolizumab in head and neck cancer.
Cancer Med
; 12(6): 6603-6614, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36479637
15.
Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis.
JCO Precis Oncol
; 7: e2200317, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37099733
16.
Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results.
Nat Med
; 29(7): 1718-1727, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37429923
17.
Evaluation of the TruSight Oncology 500 Assay for Routine Clinical Testing of Tumor Mutational Burden and Clinical Utility for Predicting Response to Pembrolizumab.
J Mol Diagn
; 24(6): 600-608, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35218944
18.
Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors.
J Immunother Cancer
; 10(1)2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35101941
19.
Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study.
J Immunother Cancer
; 10(7)2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35793874
20.
Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types.
Clin Cancer Res
; 28(8): 1680-1689, 2022 04 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34965943